MedTrace Logo

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

NCT03801200 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-02-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).

Conditions

Interventions

DRUG

Apatinib

radiotherapy with Apatinib

Sponsors & Collaborators

  • Hubei Cancer Hospital

    lead OTHER

Principal Investigators

  • Desheng Hu · Associate dean

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2021-09-10
Completion
2023-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801200 on ClinicalTrials.gov